Immunology News and Research

Latest Immunology News and Research

Genetic cause of progressive hearing loss discovered

A team led by scientists from The Scripps Research Institute has discovered a genetic cause of progressive hearing loss. The findings will help scientists better understand the nature of age-related decline in hearing and may lead to new therapies to prevent or treat the condition.

4 Sep 2009

Two new antibodies for targeting HIV virus discovered

Researchers at and associated with the International AIDS Vaccine Initiative (IAVI), at The Scripps Research Institute, and at the biotechnology companies Theraclone Sciences and Monogram Biosciences have discovered two powerful new antibodies to HIV that reveal what may be an Achilles heel on the virus. They published their work in Science this week.

3 Sep 2009

MPI Research appoints Executive Vice President of Sales and Marketing

MPI Research announced today that Thomas Laughlin will join the company as Executive Vice President of Sales and Marketing and will be a member of the company’s Corporate Management Team. Laughlin’s 30+ years of executive experience span several of the world’s largest and most successful healthcare products companies.

3 Sep 2009

National Cancer Institute awards grant to Receptor Logic for breast cancer research

Receptor Logic, Inc. announced today receipt of a Phase I Small Business Technology Transfer (STTR) Grant from the National Cancer Institute. The grant, entitled “Therapeutic Effectiveness of T-Cell Receptor mimic (TCRm™) Antibodies in Breast Cancer Treatment” will accelerate Investigational New Drug Application enabling studies surrounding lead candidate TCRm antibodies.

3 Sep 2009

New target for cancer cure identified

Researchers Dr. Marc Therrien at the Institute for Research in Immunology and Cancer (IRIC) of the Universit- de Montr-al, and Dr. Frank Sicheri, at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital in Toronto, have discovered a new target that may be instrumental in the development of new, more effective cancer therapies.

3 Sep 2009

FDA approves Meda's ASTEPRO Nasal Spray

Meda Pharmaceuticals Inc. today announced that the US Food and Drug Administration (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, for the treatment of the symptoms of seasonal and perennial allergic rhinitis (SAR and PAR). New ASTEPRO Nasal Spray 0.15% is the first nasal antihistamine to offer convenient once-daily dosing for patients who suffer from seasonal allergies.

2 Sep 2009

Nuvo Research's co-operative drug development project with Fraunhofer Institute for developing WF10

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced a co-operative drug development project with the Fraunhofer Institute for Cell Therapy and Immunology IZI in Leipzig, Germany for the preclinical and clinical development of WF10 as a potential treatment for Allergic Rhinitis.

2 Sep 2009

Cimzia approved for treating adult patients with rheumatoid arthritis

UCB Canada Inc. announced today that Health Canada has approved Cimzia, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).

1 Sep 2009

NASDAQ Stock Market issues noncompliance letter to Encorium Group

Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that on August 25, 2009, it received a letter from The NASDAQ Stock Market notifying the Company that, based on its Form 10-Q for the period ended June 30, 2009, NASDAQ has determined that the Company's stockholders' equity does not comply with the minimum $2.5 million stockholders' equity requirement for continued listing on The NASDAQ Capital Market as required by NASDAQ Marketplace Rule 5550(b)(1).

1 Sep 2009

Rodents may serve as useful models to interpret parent-offspring relationships

Researchers at the Yerkes National Primate Research Center, Emory University, have demonstrated that prairie voles may be a useful model in understanding the neurochemistry of social behavior. By influencing early social experience in prairie voles, researchers hope to gain greater insight into what aspects of early social experience drive diversity in adult social behavior.

1 Sep 2009

New clinical predictors required to determine future asthma attacks

Screening tests used to predict asthma activity in patients may have little tracking success when applied to people with persistent disease who are adhering to their health care regimens, UT Southwestern Medical Center physician report.

1 Sep 2009

Elsevier publishes second edition of Signal Transduction

Elsevier, the world-leading publisher of scientific, technical and medical information products and services, announces the publication of the new second edition of Signal Transduction edited by Bastien D. Gomperts, Ijsbrand M. Kramer and Peter E.R. Tatham.

1 Sep 2009

ViraCor-IBT Laboratories launches new influenza and respiratory virus testing service

ViraCor-IBT Laboratories today launched a new, comprehensive influenza and respiratory virus testing service that will assist physicians in detecting a range of respiratory viruses including 2009 Influenza A H1N1, or “swine flu,” as well as other influenza subtypes and common respiratory viruses such as rhinovirus, respiratory syncytial virus (RSV) and human metapneumovirus (HMPV).

31 Aug 2009

Leading experts in health and health care reform to take part in symposium

With the nation facing a $9 trillion deficit over the next 10 years, according to government estimates, the future of health care reform depends upon a neglected but critical leg of the equation: cost. Some of the nation’s leading experts in health and health care reform will provide insights into this issue when they converge in Nashville Saturday for a nonpartisan public discussion.

29 Aug 2009

CHI's first symposium to increase the understanding of its role in performing human immunologic studies

NIH’s National Heart, Lung and Blood Institute’s CENTER FOR HUMAN IMMUNOLOGY (CHI) announces the first Meeting the Human Immunology Challenge Symposium. This two-day meeting will be held September 3-4, 2009 on the NIH Campus.

28 Aug 2009

Study reveals that asthma patients fare better by taking oral controllers than inhaled corticosteroids

Mayo Clinic Proceedings published a peer-reviewed comparative effectiveness study performed by HealthCore, Inc. in its August edition. The study demonstrated that asthma patients in general had better clinical outcomes with oral controllers than inhaled corticosteroids.

27 Aug 2009

BMSN and ENTB collaborate with Therinjectto to develop a new immuno-therapeutic cancer vaccine

Bio-Matrix Scientific Group, Inc. and Its majority owned subsidiary Entest BioMedical Inc. announced today they have finalized a definitive agreement with Therinject LLC for the development of a new immuno-therapeutic cancer vaccine. Therinject LLC is engaged in the development of cancer treatments utilizing immunology based approaches.

27 Aug 2009

Viral polymerase may provide a new therapeutic target for host-adapted avian influenza

Current research suggests that viral polymerase may provide a new therapeutic target for host-adapted avian influenza. The related report by Gabriel et al, "Spread of Infection and Lymphocyte Depletion in Mice Depends on Polymerase of Influenza Virus" appears in the September 2009 issue of the American Journal of Pathology.

26 Aug 2009

HealthCore study reports that oral controllers provide better clinical outcomes for asthma patients

Mayo Clinic Proceedings published a peer-reviewed comparative effectiveness study performed by HealthCore, Inc. in its August edition. The study demonstrated that in general had better clinical outcomes with oral controllers than inhaled corticosteroids.

26 Aug 2009

Genome BC's research projects to determine efficient methods of liberating fermentable sugars from dead pine

In order to reduce the Province's greenhouse gas emissions, the BC Bioenergy Strategy is calling for greatly increased production of renewable biofuels such as ethanol, from biomass grown in BC. Two new research projects, largely funded by Genome BC, will help to answer these questions and unlock the valuable green energy found within BC's forests.

25 Aug 2009

Immunology News and Research

Latest Immunology News and Research

Genetic cause of progressive hearing loss discovered

Two new antibodies for targeting HIV virus discovered

MPI Research appoints Executive Vice President of Sales and Marketing

National Cancer Institute awards grant to Receptor Logic for breast cancer research

New target for cancer cure identified

FDA approves Meda's ASTEPRO Nasal Spray

Nuvo Research's co-operative drug development project with Fraunhofer Institute for developing WF10

Cimzia approved for treating adult patients with rheumatoid arthritis

NASDAQ Stock Market issues noncompliance letter to Encorium Group

Rodents may serve as useful models to interpret parent-offspring relationships

New clinical predictors required to determine future asthma attacks

Elsevier publishes second edition of Signal Transduction

ViraCor-IBT Laboratories launches new influenza and respiratory virus testing service

Leading experts in health and health care reform to take part in symposium

CHI's first symposium to increase the understanding of its role in performing human immunologic studies

Study reveals that asthma patients fare better by taking oral controllers than inhaled corticosteroids

BMSN and ENTB collaborate with Therinjectto to develop a new immuno-therapeutic cancer vaccine

Viral polymerase may provide a new therapeutic target for host-adapted avian influenza

HealthCore study reports that oral controllers provide better clinical outcomes for asthma patients

Genome BC's research projects to determine efficient methods of liberating fermentable sugars from dead pine

eBook: Cell-based technologies in drug discovery and Immunotherapy eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog